Overview

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

Status:
NOT_YET_RECRUITING

Trial end date:
2027-03-06

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.

Phase:

PHASE3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

ALN-PCS